EGFR and adrenal cortex carcinoma: The forest plot indicated that MKIs of Apatinib (46.2% ORR) and NOTCH inhibitors (15.4% ORR) were potential candidates, but the first-generation EGFR inhibitors, including Gefitinib and Lapatinib, might not be efficient when treating patients with R/M ACC.